SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Allogene Therapeutics, Inc. (Allogene), a biotechnology company with a mission to catalyze the next revolution of cell therapy through the advancement of allogeneic CAR T therapies for blood cancers and solid tumors, today announced a poster presentation highlighting preclinical research for its allogeneic pipeline programs. The presentation will occur during the 21st ASGCT Annual Meeting, which is taking place in Chicago May 16-19, 2018.
Presentation Details:
Title: Development of an In Vitro Cynomolgus Macaque Allogeneic
CAR T Cell Platform: Working towards a Reliable In Vivo Allogeneic Model
to Assess Safety and Efficacy (Poster No. 131)
Category:
Cancer - Targeted Gene & Cell Therapy I
Session Date & Time:
Wednesday, May 16, 2018 at 5:30 PM - Stevens Salon C, D
Authors:
Diego A. Vargas-Inchaustegui1, Rory Dai1,
Alexandre Juillerat2, Christopher Do1, Kris Poulsen1,
Thomas Pertel1, Barbra Sasu1
1Allogene Therapeutics, Inc., South San Francisco, CA,
2Cellectis,
Inc., New York, NY
Abstracts are available on the ASGCT website.
In April 2018, Allogene announced that it had acquired Pfizer’s allogeneic CAR T portfolio which included the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR T therapy that is being developed for treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is initially being developed in acute lymphoblastic leukemia (ALL) and is currently in Phase 1.
About Allogene Therapeutics
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.
Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer, Gilead and Pfizer. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
